Century Therapeutics, Inc. (IPSC)
IPSCNASDAQ-CMBiotechnology: Biological Products (No Diagnostic Substances)
$1.81
+0.1250 (+7.42%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $327.75m
- P/E
- –
- EPS, last 4 quarters
- $-0.8500
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.4350 to $3.04
- Average volume
- 769.0k
- Previous close
- $1.69
Analysts
4 coveringBuy4 buy, 0 hold, 0 sell
Targets a year out average $5.90, +226.0% from here
Earnings
next estimate $-0.1200Next report Nov 12, 2026
Sep 2025
+17.9%
Dec 2025
+10.7%
Mar 2026
+26.7%
Jun 2026
-54.5%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$36.13m | -$20.65m | -$23.68m | -$36.53m |
| Net income | -$34.43m | -$19.17m | -$21.64m | -$34.55m |
News
8 latest- Century Therapeutics Advances CNTY-813 Toward Clinical Testing With New EASD Data RTTNews · Oct 2, 2026
- Century Therapeutics Appoints IECURE CEO Joseph Truitt To Board As CNTY-813 Nears IND Filing RTTNews · Sep 10, 2026
- Century Advances CNTY-813; IND Submission On Track For Q4 2026 RTTNews · Aug 12, 2026
- Mizuho Initiates Coverage of Century Therapeutics (IPSC) with Outperform RecommendationFintel · May 27, 2026
- Century Therapeutics (IPSC) Price Target Increased by 10.75% to 4.20Fintel · Feb 3, 2026
- Are Biotech And Pharma Stocks Poised To Keep Climbing After Hitting 52-Week Highs? RTTNews · Jan 27, 2026
- Century Therapeutics (IPSC) Upgraded to Strong Buy: Here's What You Should KnowZacks · Jan 22, 2026
- FDA Grants Breakthrough Therapy Designation to ALKS' Narcolepsy DrugZacks · Jan 7, 2026
The company
Century Therapeutics (NASDAQ: IPSC) is a biotechnology company advancing a pipeline of induced pluripotent stem cell (iPSC)-derived cell therapies with the potential to meaningfully address autoimmune diseases, including type 1 diabetes, and cancer. Century's therapies are derived from its iPSC cell foundry and leverage its novel immune evasion engineering technology, Allo-Evasion. Century believes its approach to developing off-the-shelf cell therapies will expand patient access and provide advantages over existing cell therapies which will ultimately advance the course of care.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- centurytx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.